Savara Financial Statements
NASDAQ: SVRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
4.92+0.09 (+1.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Savara revenue and earnings
Savara reported a net loss of $118.8 million, compared with a loss of $95.9 million a year earlier. Diluted earnings per share came in at -$0.53.
Summary generated from market data by MetaCap's automated system. Methodology
Savara income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | 257.00K | 0 | — | 0 | 400.00K |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | -100.00% | +640.74% |
| Operating Expenses | 123.55M | 103.20M | 60.01M | 38.84M | 41.48M | 49.56M | 79.03M | 70.05M | 29.96M | 11.35M |
| Research & Development | 81.40M | 78.03M | 44.26M | 27.88M | 28.99M | 35.04M | 38.78M | 37.17M | 18.51M | 8.18M |
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | 9.34M |
| Operating Income | -123.55M | -103.20M | -60.01M | -38.84M | -41.48M | -49.30M | -79.03M | -70.05M | -29.96M | -10.95M |
| Interest Expense | — | — | — | — | — | — | — | — | 1.16M | 452.00K |
| Other Income (Expense) | 4.71M | 7.32M | 5.31M | 689.00K | -1.54M | -315.00K | 852.00K | 1.47M | -3.48M | -332.00K |
| Pretax Income | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -68.57M | -33.43M | -11.28M |
| Income Tax | 0 | 9.00K | — | — | — | — | — | -7.06M | -3.63M | -357.00K |
| Net Income | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M | -49.62M | -78.17M | -61.52M | -29.80M | -10.92M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -1.95 | -1.85 | -1.76 | -5.62 |
| EPS (Diluted) | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -1.95 | -1.85 | -1.76 | -5.62 |
| Shares Outstanding (Basic) | 222.39M | 198.19M | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 1.96M |
| Shares Outstanding (Diluted) | 222.39M | 198.19M | 165.20M | 152.77M | 133.92M | 59.31M | 40.03M | 33.30M | 17.52M | 1.96M |
| EBITDA | -123.46M | -103.07M | -59.93M | -38.81M | -41.34M | -49.05M | -78.02M | -69.52M | -29.59M | -10.85M |
| Operating Margin | — | — | — | — | — | -19182.88% | — | — | — | -2737.00% |
| Net Margin | — | — | — | — | — | -19305.45% | — | — | — | -2730.75% |
This table shows 10 annual periods of Savara's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, gross profit, operating expenses. Values in USD; B = billions, M = millions. Fiscal periods follow SVRA's reporting calendar. What is a income statement?